Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
Lossos
Izidore S
IS
Morgensztern
Daniel
D
Blaya
Marcelo
M
Alencar
Alvaro
A
Pereira
Denise
D
Rosenblatt
Joseph
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000188:drug therapy; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab